While agents targeting the eIF2α-eIF2B axis/ternary complex-mediated phenotype switching are yet to be explored, inhibitors targeting different eIF4F components have shown efficacy in preclinical melanoma models. This evidence concerns the gene EIF4G1 and melanoma.